Prospective evaluation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.

被引：1
|
作者：
Adachi, Takuya
Nouso, Kazuhiro
Miyahara, Koji
Dohi, Chihiro
Wada, Nozomu
Takeuchi, Yasuto
Kuwaki, Kenji
Onishi, Hideki
Ikeda, Fusao
Nakamura, Shinichiro
Shiraha, Hidenori
Takaguchi, Koichi
Uematsu, Shuji
Iwadou, Shouta
Takuma, Yoshitaka
Hagihara, Hiroaki
Takabatake, Hiroyuki
Takaki, Akinobu
Okada, Hiroyuki
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan
[2] Okayama Univ, Dept Gastroenterol & Hepatol, Okayama, Japan
[3] Hiroshima City Hiroshima Citizens Hosp, Hiroshima, Japan
[4] Kagawa Prefectural Cent Hosp, Takamatsu, Kagawa, Japan
[5] Sumitomo Besshi Hosp, Nihama City, Japan
[6] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15674
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15674
引用
收藏
页数：6
相关论文
共 50 条
  • [1] A multicenter analysis of prognostic factors in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib.
    Smith, Alan D.
    Chan, Kelvin K.
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Effect of specialized nursing intervention on the prognosis of hepatocellular carcinoma patients treated with sorafenib.
    Pang, Xufeng
    Li, Guizhi
    Lv, Yaqing
    Wang, Juanjuan
    Wei, Lili
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (02): : 791 - 796
  • [3] A population-based analysis of prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Journal
    Smith, Alan D.
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [4] KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
    Zhu, Andrew X.
    Finn, Richard S.
    Cattan, Stephane
    Edeline, Julien
    Ogasawara, Sadahisa
    Palmer, Daniel H.
    Verslype, Chris
    Zagonel, Vittorina
    Rosmorduc, Olivier
    Vogel, Arndt
    Sarker, Debashis
    Verset, Gontran
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Ebbinghaus, Scot
    Ma, Junshui
    Siegel, Abby B.
    Cheng, Ann-Lii
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Pretreatment neutrophil to lymphocyte ratio and prognosis of patients with advanced hepatocelullar carcinoma treated with sorafenib.
    Fonseca, Leonardo Gomes
    Barroso-Sousa, Romualdo
    Blanco, Bruna Paccola
    Valente, Gabriel Luls
    Freltas Melro Braghlroll, Maria Ignez
    Flesch Pfiffer, Tullo Eduardo
    Sabbaga, Jorge
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.
    Herman, Michael
    Zhang, Yuhua
    Wang, Lisa
    Sim, Hao-Wen
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
    Pinter, M.
    Sieghart, W.
    Hucke, F.
    Graziadei, I.
    Vogel, W.
    Maieron, A.
    Koenigsberg, R.
    Weissmann, A.
    Kornek, G.
    Matejka, J.
    Stauber, R.
    Buder, R.
    Gruenberger, B.
    Schoeniger-Hekele, M.
    Mueller, C.
    Peck-Radosavljevic, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 949 - 959
  • [8] Evaluation of mRECIST and AFP ratio for stratification of prognosis of patients treated with sorafenib for advanced hepatocellular carcinoma
    Kawaoka, Tomokazu
    Aikata, Hiroshi
    Takahashi, Shoichi
    Takaki, Shintaro
    Hiramatsu, Akira
    Chayama, Kazuaki
    HEPATOLOGY, 2012, 56 : 620A - 620A
  • [9] SAFETY PROFILE OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): A PROSPECTIVE EVALUATION
    Dhorancy, Sebastien
    Cattan, Stephane
    Romano, Olivier
    Conva, Valerie
    Castel, Helene
    Boleslawski, Emmanuel
    Truant, Stephanie
    Hebbar, Mohammed
    Pruvot, Francois R.
    Mathurin, Philippe
    HEPATOLOGY, 2009, 50 (04) : 1099A - 1099A
  • [10] A comparison of prognostic systems in hepatocellular carcinoma treated with sorafenib.
    Bagnall, Elizabeth Marie
    Gresham, Gillian
    Czaykowski, Piotr
    Chan, Kelvin K.
    Fung, Jennifer
    Cuvelier, Susan
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345